|1.||Komori, K: 1 article (11/2000)|
|2.||Okazaki, J: 1 article (11/2000)|
|3.||Ozeki, Y: 1 article (11/2000)|
|4.||Kawasaki, K: 1 article (11/2000)|
|5.||Sugimachi, K: 1 article (11/2000)|
11/01/2000 - "These results demonstrate the efficacy of OPC-29030 in reducing the degree of intimal hyperplasia under PR conditions, but not under hyperlipidemic conditions. "
11/01/2000 - "However, in the HL group, the intimal hyperplasia in both the OPC-29030 and control groups showed a remarkable degree of intimal hyperplasia. "
11/01/2000 - "The efficacy of OPC-29030, a newly developed inhibitor of 12(S)-hydroxyeicosatetraenoic acid (12-HETE) production, was evaluated on intimal hyperplasia of experimental autologous vein grafts in a distal poor-runoff model and a hyperlipidemic model in rabbits. "
11/01/2000 - "In the in vivo study in the PR group, the intimal hyperplasia and the plasma 12-HETE levels in the OPC-29030 group were significantly inhibited, compared with those of the control group. "
11/01/2000 - "The mechanism of reducing the intimal hyperplasia may be that OPC-29030 inhibited 12-HETE production, which did not inhibit proliferation while inhibiting migration of the smooth muscle cell. "